Tislelizumab versus chemotherapy as second-line treatment for advanced or metastatic esophageal squamous cell carcinoma (ESCC, RATIONALE 302): Impact on health-related quality of life (HRQoL)

被引：1

作者：

Van Cutsem, Eric

Kato, Ken

Ajani, Jaffer A.

Shen, Lin

Xia, Tianyu

Ding, Ningning

Zhan, Lin

Barnes, Gisoo

Kim, Sung-Bae

机构：

[1] Univ Leuven KUL, Leuven, Belgium

[2] Univ Hosp Gasthuisberg, Leuven, Belgium

[3] Natl Canc Ctr, Dept Head & Neck Esophageal Med Oncol, Tokyo, Japan

[4] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA

[5] Peking Univ, Canc Hosp & Inst, Dept Gastrointestinal Oncol, Beijing, Peoples R China

[6] BeiGene Ltd, Cambridge, MA USA

[7] BeiGene Ltd, Zhongguancun Life Sci Pk, Beijing, Peoples R China

[8] BeiGene Ltd, San Mateo, CA USA

[9] BeiGene Ltd, Emeryville, CA USA

[10] Univ Ulsan, Asan Med Ctr, Coll Med, Seoul, South Korea

来源：

关键词：

D O I：

10.1200/JCO.2022.40.4_suppl.268

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

268

引用

页数：3